Axis Direct Broker Research reports

We maintain our BUY rating on the stock.

We maintain our BUY recommendation on the stock.

Asian Markets are trading positively after the U.S. court blocks Trump's reciprocal' tariffs. Nikkei, Hang Seng, and Shanghai are trading positively by 1.58%, 0.19%, and 0.40%, respectively.

We recommend a HOLD rating (unchanged) on the company.

We downgrade from BUY to HOLD rating on the stock.

Asian Markets are mostly trading positively, mirroring the global markets. Nikkei and Shanghai are both trading positively by 0.52% and 0.12% respectively, whereas Hang Seng is trading negatively by 0.26%.

We maintain our BUY rating on the stock.

We maintain our BUY recommendation on Aurobindo Pharma with a TP of Rs 1,500/share.

We recommend a BUY rating on the stock with a TP of Rs 425/share, implying an upside of 10% from the CMP.

With a 2% downside from the CMP, we maintain our HOLD rating.

We maintain our BUY recommendation on the stock.

We maintain our BUY recommendation on the stock.

With an upside potential of 6% from the CMP, we downgrade the stock from BUY to HOLD.

We maintain our BUY rating on the stock.

We retain the BUY rating.

We maintain our BUY rating on the stock.

We change our rating on the stock from BUY to HOLD.

We maintain our BUY recommendation on the stock at reasonable valuations.

We maintain our BUY recommendation on the stock.

Asian markets were trading higher after the US Federal Reserve kept rates unchanged. The Nikkei, Hang Seng, and Shanghai indices rose by 0.22%, 0.66%, and 0.20%, respectively.